| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Institut de Médecine et d'Epidémiologie Tropicales/INSERM U13, Hôpital Claude Bernard, 75944 Paris Cédex 19, France [B. L., C. G.]; INSERM U152, Hôpital Cochin, 75014 Paris, France [L. S., S. B., J. P. L.]; INSERM U73, Château de Longchamps, 75016 Paris, France [P. C.]; Instituto de Ciencias Biomedicas, Universidade do Porto, Portugal [M. D. G. P.]; Faculté de Médecine de Dakar, Sénégal [J. M. A., L. D.]; Hôpital de Bangui, Central African Republic [M. L. F.]; Faculté de Pharmacie de Monastir Tunisia [M. J.]; Equipe Médicale de Tokora, Uganda [E. M.]; Office de la Recherche Scientifique et Technique Outre Mer, Brazzaville, the Congo [F. N.]; Service de pathologie infectieuse, Hôpital de Constantine, Algeria [B. N.]; Institut Pasteur de Tananarive, Madagascar [M. R.]
Using a radioimmunoassay to detect HTLV-I protein antibodies of molecular weight 24,000, we screened populations from Algeria (140 subjects), Tunisia (442), Mali (69), Senegal (415), Uganda (135), the Central African Republic (77), the Congo (360), and Madagascar (193). Only four subjects were positive (1 from Senegal, 1 from Uganda, 2 from the Congo). This is a much lower figure than that found by others in Africa by the enzyme-linked immunosorbent assay technique. In addition, 319 Portuguese blood donors (46 of whom have lived in Angola or Mozambique) were screened using the same radioimmunoassay. All were negative.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |